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Up to half of all patients with the clinical features of heart failure have preserved left ventricular ejection fraction 
(HFpEF), defined as an EF ≥50%.1–3 Mortality rates in patients 
with HFpEF are similar to those in patients with reduced EF 
(HFrEF)1,2,4 and are due largely to cardiovascular death.4,5 In 
contrast to HFrEF, there are no proven therapies for HFpEF 
despite the increasing prevalence and hospitalization rate.2,3 
The failure of multiple investigational therapies to influence 
survival or to affect symptoms in HFpEF likely reflects het-
erogeneous case inclusion (including geographic variation in 
trial recruitment), suboptimal drug administration with regard 
to dose, stage or endophenotype of disease, or an incomplete 
conception of disease pathophysiology.6–9
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HFpEF has been conceptualized, in part, as a disorder of dia-
stolic function, reflecting impairments in active relaxation and 
intrinsic myocardial compliance.10 More broadly, these patients 
have impairments in ventricular-arterial coupling and of con-
tractile function, albeit insufficient to reduce global left ventric-
ular EF, and abnormally low skeletal muscle O2 extraction.11,12 
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Given the critical contribution of diastole to ventricular filling 
and coronary perfusion, reduction of heart rate, with a view to 
prolonging diastole, especially in atrial fibrillation, has been 
advocated as a therapeutic strategy to mitigate symptoms in 
HFpEF13 and has been endorsed by guidelines.14 However, 
increased heart rate is the major physiological contributor to the 
rise in cardiac output necessary to meet the metabolic demands 
of exercise,15 the capacity for which is substantially reduced 
in both HFpEF and HFrEF.16 Mechanistic studies of patients 
with HFpEF subject to exercise stress have implicated chro-
notropic incompetence as a potential contributor to impaired 
cardiac output reserve and thereby likely to contribute to the 
exertional dyspnea and effort intolerance characteristic of the 
syndrome.16–19 Accordingly, we sought to test the hypothesis 
that heart rate reduction improves exercise tolerance as assessed 
by peak oxygen consumption ( V o2 peak).
We performed a placebo-controlled, crossover, clinical study 
to evaluate the effects of short-term selective heart rate reduc-
tion with ivabradine (2 weeks), an inhibitor of the sinoatrial pace-
maker funny current (If) considered devoid of effects on cardiac 
contractility,20 on the exercise performance of a homogeneous 
group of subjects with exercise-limited HFpEF. To substantiate 
the generalizability of the results and to inform our understanding 
of mechanisms responsible for exercise limitation, we performed 
a parallel study in a matched asymptomatic hypertensive group 
representing less advanced pathophysiology.
Methods
Study Design
We undertook a prospective, double-blind, placebo-controlled, 
randomized, crossover trial at 2 UK academic hospitals: the John 
Radcliffe Hospital (Oxford) and the Aberdeen Royal Infirmary. The 
study was designed to assess the effect of short-term administration 
of ivabradine on V o2 peak and other parameters of exercise perfor-
mance in a well-defined cohort of patients with HFpEF and a com-
parator asymptomatic hypertensive group. The study was approved 
by the Ethics Service committees in Aberdeen and Oxford (South 
Central). All participants provided written informed consent to study. 
Detailed methods are included in the online-only Data Supplement.
Study Patients
Consensus has not been reached on the optimal method(s) with which 
to define HFpEF patients; however, there is broad agreement that these 
dynamic disturbances during exercise cannot be predicted from resting 
measures of diastolic function.21 For these reasons, our inclusion criteria 
corresponded to those previously used,22 with rigorous cardiopulmonary 
exercise testing criteria to establish that the patients were objectively 
limited compared with age- and sex-predicted normal values.
HFpEF was defined according to the presence of both symptoms 
and signs of HF and EF ≥50%, a nondilated left ventricle and relevant 
structural heart disease in the form of left ventricular hypertrophy, left 
atrial enlargement, or evidence of diastolic dysfunction on echocar-
diography (mitral inflow E/A ratio, e′ measured at the mitral annulus, 
and E/e′ ratio).23 Eligible patients with HFpEF were at least 60 years 
of age with subjective exercise limitation owing to breathlessness or 
fatigue and objective evidence of exercise limitation as a measured 
V o2 peak on cardiopulmonary exercise testing of <80% predicted for 
age and sex, with an appropriate pattern of gas exchange.24,25
Screening and Intervention
Eligible participants underwent screening assessment by history 
taking and physical examination, quality-of-life assessment mea-
sured by the Minnesota Living With Heart Failure Questionnaire,26 
biochemical blood analysis, 12-lead ECG, transthoracic echocardiog-
raphy, spirometry, and cardiopulmonary exercise testing.
We screened 65 patients for the HFpEF group and selected 34 
matched asymptomatic hypertensive patients from a hypertension data-
base over a 2-year period from December 2011 through January 2014 
(Figure 1). Of these, 30 patients were found to be eligible to enter the 
HFpEF group, and all 34 patients were eligible for the asymptomatic 
hypertension group. The first 24 consecutive patients took part in the 
HFpEF group, of which 2 participants were excluded in the final analy-
sis: 1 patient did not complete the study and dropped out during the sec-
ond visit, and the other was excluded because of suboptimal exercise 
testing based on a respiratory exchange ratio of 0.81 during the second 
visit. Twenty-two asymptomatic hypertensive patients consented and 
participated in the study, and all were included in the final analysis. In 
line with existing trial protocols of ivabradine in HFrEF aiming for a 
heart rate target of 50 to 60 bpm,27,28 eligible participants were randomly 
assigned through block randomization to receive either ivabradine 7.5 
mg twice daily or matching placebo tablets for 2 weeks (period 1). At 
the end of period 1, all screening assessments were repeated; in addi-
tion, cardiovascular magnetic resonance imaging was performed in 
the HFpEF cohort. After a 2-week washout period, subjects were then 
assigned to the alternative treatment arm (placebo or ivabradine) for a 
further 2 weeks (period 2). At the end of this, all period 1 assessments 
were repeated. Participants, investigators, and outcome assessors were 
all blinded to treatment allocation.
Study End Points
The predefined primary end point was the change in Vo2 peak. 
Secondary end points were changes in Doppler-derived E/e′, 
Figure 1. Flow diagram of the study. CPEX indicates 
cardiopulmonary exercise testing; ECHO, echocardiography; 
HFpEF, heart failure with preserved ejection fraction; and MRI, 
magnetic resonance imaging.
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brain natriuretic peptide levels, and quality of life assessed by the 
Minnesota Living With Heart Failure Questionnaire.
Statistical Analysis
For a crossover study design, power calculation indicated that to 
detect a mean absolute difference in Vo2 peak of 2.5 mL·kg−1·min−1 (SD, 2.5 mL·kg−1·min−1), 22 patients could provide 90% power 
at an overall 2-sided α level of 0.05. Continuous variables are 
reported as mean±SD. Data sets were evaluated for normality by the 
Kolmogorov-Smirnov test. Comparisons between HFpEF and the 
asymptomatic hypertensive group were assessed by a 2-tailed Student 
t test. The comparisons between ivabradine and placebo treatments 
within patient groups were assessed by a 2-tailed paired Student t 
test. All statistical analyses were performed with the use of SPSS 
Statistics, version 19 (IBM). A value of P≤0.05 with a 2-tailed test 
was considered statistically significant.
Results
Baseline Clinical Characteristics
Baseline clinical characteristics of the patients are shown in 
Table 1. Compared with the hypertensive group, the patients 
with HFpEF were older (74.6 versus 66.9 years; P=0.0001), 
were more likely to be female (65% versus 23%; P=0.014), 
and had a lower proportion of hypertension (50% versus 100%; 
P=0.0002). Cardiovascular drug therapy was similar between 
groups, but there was a significantly greater use of calcium 
channel blockers in the hypertensive cohort (55% versus 5% 
in the HFpEF cohort; P=0.0006). Three HFpEF patients but 
no hypertensive individuals were taking β-blockers (P=0.23). 
All HFpEF patients but none in the hypertension group scored 
significantly on the Minnesota Living With Heart Failure 
Questionnaire at baseline. There were no differences in rest-
ing plasma brain natriuretic peptide. The baseline echocardio-
graphic characteristics of HFpEF patients are shown in Table 
I in the online-only Data Supplement.
Response to Exercise
Cardiopulmonary exercise testing of HFpEF patients at base-
line revealed a significantly lower Vo2 peak (16.1 versus 
27.0 mL·kg−1·min−1 [P<0.0001] despite satisfactory effort 
indicated by a respiratory exchange ratio >1.0), anaerobic 
threshold (11.5 versus 20.6 mL·kg−1·min−1; P<0.0001), and 
maximal workload achieved (4.5 versus 7.7 metabolic equiva-
lents; P<0.0001) compared with the hypertensive group but 
an increased ventilatory response to exercise, as indicated 
by a higher ratio of minute ventilation to carbon dioxide 
production ( VE / Vco2; Table 2). Despite being asymptom-
atic, the hypertensive cohort had Vo2 peak values that were 
below mean age- and sex-predicted normal values (28.0 
mL·kg−1·min−1). HFpEF patients had marked chronotropic 
dysfunction with lower peak exercise heart rates (129 versus 
145 bpm; P<0.0001).
Selective Heart Rate Lowering With Ivabradine in 
the HFpEF Cohort
Table 3 and Table II in the online-only Data Supplement show 
the comparison of the effects of ivabradine versus placebo on 
resting hemodynamic, cardiac imaging, and exercise param-
eters in the HFpEF cohort. Ivabradine reduced the mean rest-
ing heart rate by 20 bpm (77 to 57 bpm; P<0.0001) without 
any effect on blood pressure or left ventricular EF. Similarly, 
ivabradine treatment reduced the chronotropic response to 
exercise (peak heart rate, 129 versus 107 bpm; P<0.0001). 
The heart rate reduction was accompanied by reduced peak 
oxygen consumption in the majority of HFpEF patients (19 
patients had a reduction in the Vo2 peak), with a diminution 
in the Vo2 peak from 15.9 to 14.8 mL·kg−1·min−1 (P=0.003), 
without significantly affecting VE / Vco2 slope or the anaerobic 
threshold. Moreover, a paired comparison of the changes in 
Vo2 peak resulting from the 2-week intervention blocks dem-
onstrated a consonant lowering in the ivabradine group (−2.1 
versus 0.9 mL·kg−1·min−1; P=0.003; Figure 2). Compared 
with placebo, ivabradine treatment induced small but sig-
nificant increases in the transmitral E/A ratio (0.6 versus 
0.65; P=0.026) and mean e′ velocity (4.5 versus 5.4 cm/s; 
P=0.002), with no effect on the E/e′ ratio, ratio of myocardial 
phosphocreatine to adenosine triphosphate, or symptomatic 
status (Minnesota Living With Heart Failure Questionnaire; 
Table 3).
To assess the influence of ivabradine on submaximal 
exercise performance in patients with HFpEF, an analysis of 
the relationship between oxygen consumption and ventilation, 
defined as the oxygen uptake efficiency slope (OUES), 
was also undertaken (Table II and Figure I in the online-
only Data Supplement). OUES is a submaximal measure of 
Table 1. Clinical and Demographic Characteristics of the 
HFpEF and Asymptomatic Hypertensive Cohorts at Baseline
HFpEF
(n=22)
Hypertensive
(n=22) P Value
Age, y 74.6±5.9 66.9±5.2 0.0001
Women, n (%) 14 (65) 5 (23) 0.014
Body mass index, kg/m2 29.9±6.2 26.7±2.9 0.036
NYHA class I, n (%) … 22 (100)
NYHA class II, n (%) 22 (100) …
Medical history, n (%)
  Hypertension 11 (50) 22 (100) 0 0.0002
  Diabetes mellitus 2 (10) 3 (14) 1.0
  Dyslipidemia 9 (41) 1 (5) 0.009
Medications, n (%)
  ACE-I/ARB-II 13 (59) 15 (68) 0.75
  β-Blockers 3 (14) 0 0.23
  Statin 10 (46) 10 (46) 1
  Calcium blockers 1 (5) 12 (55) 0.0006
  Diuretics 14 (64) 8 (36) 0.13
  Oral hypoglycemic agents 1 (5) 0 1
Biochemical
  Hemoglobin, g/dL 13.6±1.3 14.2±0.9 0.07
  Creatinine, μmol/L 81.5±30.4 77.1±13.9 0.56
  Blood glucose, mmol/L 5.5±0.9 5.5±0.9 0.84
  Total cholesterol, mmol/L 4.5±0.9 4.5±0.9 0.89
  BNP, pmol/L 13.4 (7.5–24.4) 16.4 (11.1–31.7) 0.10
Values are mean±SD, percentages, or median (quartiles 1–3). ACE-I 
indicates angiotensin-converting enzyme inhibitor; ARB-II, angiotensin-receptor 
antagonist II; BNP, brain natriuretic peptide; HFpEF, heart failure with preserved 
ejection fraction; and NYHA, New York Heart Association.
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cardiorespiratory reserve less sensitive to exercise duration 
and has strong prognostic value in HF.29 Compared with 
placebo, an assessment of the OUES at 75% of the duration 
of exercise identified a significant reduction with ivabradine 
[1834 versus 1621 (mL/min O2)/(L/min VE); (P=0.04)].
Selective Heart Rate Lowering With Ivabradine in 
the Asymptomatic Hypertensive Cohort
As with the HFpEF group, administration of ivabradine at 
7.5 mg twice daily significantly reduced resting heart rate 
compared with placebo (from 74 to 61 bpm; P=0.001). Peak 
exercise heart rate was blunted by ivabradine use (145 ver-
sus 127 bpm; P=0.003). Ivabradine use was associated with a 
statistically nonsignificant reduction in the primary end point, 
Vo2 peak (26 versus 24.5 mL·kg−1·min−1; P=0.47; Table 4 and 
Table III in the online-only Data Supplement). Compared with 
placebo, ivabradine treatment was associated with a small but 
significant increase in the VE/ Vco2 ratio (27.4 versus 29.2; 
P=0.004) but did not affect the anaerobic threshold or peak 
workload.
Discussion
We undertook a short term, placebo-controlled, randomized, 
crossover study examining the effect of selective heart rate 
lowering with the If inhibitor ivabradine on exercise capacity 
in a well-defined cohort of patients with symptomatic HFpEF. 
With individuals acting as their own controls, we found that 
2 weeks of heart rate reduction with ivabradine at a dose of 
7.5 mg twice daily in patients with HFpEF almost uniformly 
exacerbated already abnormal exercise physiology, resulting 
in a significant reduction in the primary end point, V o2peak.
Consistent with previous reports,16–19 our cohort of 
HFpEF patients had poor exercise tolerance, a significantly 
impaired peak oxygen uptake, low V o2 at the anaerobic 
threshold, increased ventilatory response, and a reduc-
tion of the chronotropic response to exercise. Because of 
the broader pathogenesis of HFpEF, including prominent 
defects in skeletal muscle metabolism,11,12 our patients with 
HFpEF were not diagnosed on the basis of resting diastolic 
dysfunction but rather on the basis of subjective exercise 
limitation with normal left ventricular EF and the absence of 
significant valvular disease, together with objective exercise 
limitation. In the Treatment of Preserved Cardiac Function 
Heart Failure With an Aldosterone Antagonist (TOPCAT) 
study, of 935 patients with HFpEF, diastolic function was 
normal in approximately one third of gradable participants.30 
We also have observed a poor agreement between exercise 
E/E′, cardiopulmonary exercise testing categorization, and 
current criteria based on resting diastolic function.31 We and 
others have found that HFpEF is characterized by dynamic 
disturbances of left ventricular active relaxation during 
exercise.32–34 Furthermore, plasma brain natriuretic peptide 
is often relatively normal at rest in HFpEF, especially in 
those with a high body mass index in whom brain natriuretic 
Table 2. Baseline Hemodynamics and Cardiopulmonary Exercise Testing Characteristics 
of HFpEF and Asymptomatic Hypertensive Cohort
HFpEF
(n=22)
Hypertensive
(n=22) P Value
Heart rate (rest), bpm 75±12 78±14 0.36
Heart rate (peak), bpm 127±19 159±14 < 0.0001
Systolic BP, mm Hg 148±19 147±7 0.91
Diastolic BP, mm Hg 83±6 82±12 0.82
V o2 peak, mL·kg
−1·min−1 16.1 (15.0–18.2) 27.0 (22.5–31.2) < 0.0001
Percentage of predicted V o2 max, %
66 96 0.009
VE / V co2
34.4±6.1 27.3±3.4 < 0.0001
Anaerobic threshold, mL·kg−1·min−1 11.5±2.4 20.6±4.8 < 0.0001
RER 1.08±0.08 1.17±0.06 0.0002
Values are mean±SD, percentages, or median (quartiles 1–3). BP indicates blood pressure; HFpEF, heart failure 
with preserved ejection fraction; RER, respiratory exchange ratio; and VE / V CO2, ratio of minute ventilation to 
carbon dioxide production.
Figure 2. Effect of ivabradine on V o2 peak in 
the heart failure with preserved ejection fraction 
(HFpEF) cohort. Depicts the change in V o2 peak 
(mL·kg−1·min−1) with placebo (left) and ivabradine 
(right; ivabradine vs placebo, P=0.003) in the 
HFpEF cohort.
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peptide appears to be suppressed but rises dramatically on 
exercise (unpublished data).31,34,35
The choice of Vo2 peak as the primary end point in this 
study is supported by its objective measurement of cardiac 
reserve, its robust correlation with survival,36 and the difficul-
ties in obtaining a true maximal oxygen uptake ( Vo2max), 
which relies on exercise to absolute exhaustion with plateau-
ing of oxygen uptake despite continued exercise.29 In com-
mon with Vo2max, 
Vo2 peak is effort dependent and does 
not provide insight into potential differences in submaximal 
exercise capacity that may be more reflective of the levels of 
exertion that result in symptoms in HF patients. To address 
this possibility, we also evaluated a measure of submaximal 
cardiopulmonary reserve, the OUES, the value of which has, 
unlike Vo2, been shown to be relatively independent of exer-
cise duration and an even more powerful predictor of prog-
nosis than conventional measures of exercise performance.29 
We found that ivabradine treatment also significantly reduced 
submaximal cardiorespiratory reserve in HFpEF. Although 
there was a significant change in certain parameters of exer-
cise capacity, ivabradine treatment did not discernibly alter the 
cardiac energetic status (ratio of phosphocreatine to adenosine 
triphosphate) of the HFpEF or hypertensive patients.
In contrast to the Class Ia evidence in HFrEF, limited 
evidence-based treatment options exist for the management 
of HFpEF. Current therapy includes heart rate reduction, 
a strategy based on physiological observations dating to 
the late 19th century that, primarily at higher heart rates, 
shortening of the diastolic filling period impairs cardiac 
filling and results in lower stroke volumes.37 The findings 
from the present study question this widely held approach, 
indicating that even short-term selective heart rate lower-
ing in the presently defined population of HFpEF patients 
acts to impair exercise capacity, not least as the relation-
ship between decreasing heart rate and increasing stroke 
volume is asymmetrical. Moreover, the observation that 
despite ameliorating some measures of cardiac filling (eg, 
e′), heart rate reduction almost uniformly adversely affects 
exercise tolerance highlights the need for a broader concep-
tualization of HFpEF as a chronic, complex disorder of inte-
grated cardiovascular reserve rather than a purely diastolic 
disease.11,12,16,38
Kosmala et al13 reported increased exercise capac-
ity in patients with HFpEF after short-term treatment with 
ivabradine. The reasons underlying the discrepancy with the 
present study are unclear but may reflect the younger popu-
lation studied (mean age, 67 years), atypical of the clinical 
population seen with HFpEF, shorter duration, and lower dose 
of ivabradine (7 days of 2.5–5 mg twice daily, resulting in 
a reduction in resting heart rate of 10 bpm), which did not 
appear to affect peak heart rate response to exercise and per-
haps study design (not crossover). Our patients, being older 
and at an age more typical of the HFpEF population, with 
advanced chronotropic incompetence and diminished stroke 
volume reserve (a largely fixed stroke volume) were more sen-
sitive to heart rate reduction.
The present proof-of-concept study was not designed to 
address whether selective heart rate slowing had longer-term 
effects on survival or hospitalization. However, the significant 
and consistent reduction in multiple metabolic stress test-
ing parameters linked to mortality in HF, including reduced 
Vo2 peak, increased VE  / Vco2,39 low chronotropic response,39 
and reduced OUES,29 suggests the need for caution with indis-
criminate heart rate reduction in this population of patients. 
Harmful off-target effects beyond the inhibition of sinoatrial 
If are possible. Indeed, subgroup analyses of the Effects Of 
Table 3. Effect of Ivabradine Versus Placebo on Cardiac Imaging and Exercise 
Parameters in the HFpEF Cohort
Placebo
(n=22)
Ivabradine
(n=22) P Value
Change in V o2 peak during each arm 
of treatment, mL·kg−1·min−1
0.9 (−0.6 to 2.1) −2.1 (−2.9 to 0) 0.003
V o2 peak, mL·kg
−1·min−1 15.9 (14.9 to 18.4) 14.8 (13 to 17.4) 0.003
LVEF, % 64.4±8 66.6±4.5 0.23
e′ (mean of septal and lateral), cm/s 4.5±1.1 5.4±1.5 0.002
E/e′ ratio 10.4±2.5 10.7±2.4 0.56
MLHFQ 20.6±16.1 21.7±16.9 0.55
Values are mean±SD, percentages, or median (quartiles 1–3). HFpEF indicates heart failure with 
preserved ejection fraction; LVEF, left ventricular ejection fraction; and MHLFQ, Minnesota Living With 
Heart Failure Questionnaire.
Table 4. Effect of Ivabradine Versus Placebo on Cardiac 
Imaging and Exercise Parameters in the Asymptomatic 
Hypertensive Cohort
Placebo
(n=22)
Ivabradine
(n=22) P Value
Change in V o2 peak during each 
arm of treatment, mL·kg−1·min−1
1 (−1 to 4) −1.5 (−5.3 to 1) 0.08
V o2 peak, mL·kg
−1·min−1 26 (21 to 29) 24.5 (21.5 to 29.5) 0.47
LVEF, % 65.9±9.3 67.7±9.3 0.43
e′ (mean of septal and lateral), cm/s 7.2±1.9 8.2±2.2 0.12
E/e′ ratio 10.6±3.6 11.2±4.5 0.61
MLHFQ 0 (0 - 0.3) 0 (0 – 0) 1
Values are mean±SD, percentages, or median (quartiles–3). HFpEF indicates 
heart failure with preserved ejection fraction; LVEF, left ventricular ejection 
fraction; and MHLFQ, Minnesota Living With Heart Failure Questionnaire.
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Ivabradine in Patients With Stable Coronary Artery Disease 
Without Heart Failure (SIGNIFY) trial using ivabradine sug-
gested a signal for cardiovascular harm in stable coronary artery 
disease.40 However, we speculate that we are observing mecha-
nism-related drug effects and that reducing heart rate with other 
agents (eg, β-adrenergic blockade) may confer similar or more 
profound adverse effects in HFpEF as a result of their impact on 
heart rate and exercise-dependent ventricular lusitropy.41
The following represent potential limitations of our study. 
First, the sample size studied was small, but the treatment 
was not found to be beneficial in either group. Importantly, 
in this crossover study, we observed no evidence of a car-
ryover or period effect; the washout period of 2 weeks (336 
hours) exceeds the biological half-life of ivabradine (2 hours). 
Nevertheless, the study needs to be replicated in a larger clini-
cal trial examining a well-defined homogeneous cohort pow-
ered to look at mortality and morbidity end points that may 
support this and point to alternative strategies to improve exer-
cise intolerance. Second, the heart rate reduction of 20 bpm in 
our study group was greater than previously studied in trials 
using ivabradine. A beneficial effect resulting from a lesser 
heart rate reduction cannot be excluded.
Conclusion
The results of the present study do not support a general strat-
egy of heart rate reduction in HFpEF and question its role in 
improving symptoms in these patients.
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CLINICAL PERSPECTIvE
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly 50% of all the heart failure, with mortality fig-
ures now comparable to those in patients with heart failure with reduced ejection fraction. Despite this unmet clinical need, 
our limited understanding of the broad systemic pathophysiology has translated into a lack of proven therapies for HFpEF. 
Predicated on the hypothesis that heart rate reduction promotes diastolic filling with corresponding benefits in diastolic 
function in HFpEF, we investigated the influence of heart rate reduction with ivabradine in these patients in a double-blind 
crossover trial. Ivabradine is a particularly useful agent in this context because it acts on the If channels in the sinoatrial 
node and lowers the heart rate without substantially affecting cardiac contractility. The diagnosis of HFpEF was made with 
conventional echocardiographic criteria and with cardiopulmonary exercise testing to capture the dynamic impairments of 
physiology characteristic of HFpEF. We found heart rate reduction with ivabradine to have a largely consistently detrimental 
effect on peak oxygen uptake and on submaximal exercise capacity. Although a larger clinical end-point study is required, 
we believe that this report has implications for the widespread practice of heart rate reduction in this context.
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SUPPLEMENTAL MATERIAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUPPLEMENTAL METHODS 
Resting transthoracic echocardiography was undertaken using a Philips iE33 system (Philips 
Medical Systems, The Netherlands) in accordance with ESC guidelines.1 Diastolic 
evaluation was in accordance with joint recommendations of the European Association and 
American Society of Echocardiography2 and included measurement of peak early (E) and 
late (A) diastolic mitral inflow velocities, the deceleration time of the early filling velocity (DT), 
tissue Doppler mitral annular early (e’) and late (a’) diastolic velocities with subsequent 
calculation of E/e’ (e’ taken as average of septal and lateral annular velocities). All 
measurements were averaged from three consecutive cardiac cycles and images acquired 
by the same experienced sonographer for each subject at every visit. 
Cardiopulmonary exercise testing was undertaken using a symptom-limited erect treadmill or 
bicycle exercise protocol (according to patient suitability) with simultaneous respiratory gas 
analysis, as described.3, 4 All exercise protocols were undertaken on the same platform once 
selected for an individual patient. Direct measurements of oxygen consumption (VO2), 
carbon dioxide production (VCO2) and minute ventilation (VE) were made. An incremental 
protocol was utilised whereby speed and inclination (for treadmill exercise) or resistance and 
speed (for bicycle exercise) were gradually increased every minute during continual blood 
pressure and ECG measurement. Subjects were encouraged to exercise to exhaustion, with 
a corresponding adequate respiratory exchange ratio achieved as a requirement for 
satisfactory effort. Exercise was terminated at subject request due to fatigue or dyspnoea. 
Peak oxygen consumption (VO2 peak) was determined by averaging VO2 measures over 30 
seconds of peak exercise. The oxygen uptake efficiency slope was defined as the regression 
slope (a) of VO2 against VE plotted on a semilogarithmic scale such that VO2 = a log VE + b.
5  
CMR at Oxford was performed on a Siemens 3T Trio MR system (Erlangen, Germany) for 
assessment of cardiac volumes, mass and function from SSFP short-axis stacks using 
Argus post-processing software (Siemens Healthcare, Erlangen, Germany) only in the 
HFpEF cohort. In Aberdeen, a similar protocol was performed on a 1.5 T Philips Intera and 
Achieva systems (Philips Medical Systems, Best, The Netherlands). Cine images were 
acquired using standard Steady State Free Precession (SSFP) imaging. For 31P 
spectroscopy, subjects were placed in the prone position, with the heart approximately 
centred on the middle of a 31P coil. 31P-MR spectroscopy was performed with 3D acquisition-
weighted chemical shift imaging, using ultra-short time (UTE)-CSI. Correction factors for 
saturation and muscle contamination were applied. The area under each resonance is 
proportional to the amount of each 31P nucleus species in the heart, allowing direct 
quantification of the relative concentrations of ATP and phosphocreatine. 
Exclusion criteria for both cohorts included: LV EF < 50%; inability to perform exercise 
testing; inability to tolerate CMR, e.g. due to claustrophobia or inability to lie flat; contra-
indications to CMR, including the presence of implantable devices, internal cardioverter-
defibrillator, cranial aneurysm clip, metallic ocular foreign body or known hypersensitivity to 
gadolinium; the presence of other significant cardiac disease, including ischemic, valvular, 
pericardial disease or cardiomyopathy (hypertrophic, dilated or restrictive); asthma; second 
or third degree atrioventricular block; sick sinus syndrome; atrial fibrillation; significant resting 
bradycardia (heart rate < 60 beats/minute); objective evidence of lung  disease on lung 
function testing; or significant renal impairment (estimated GFR < 30 mL per minute per 1.73 
m2 body surface area). 
The hypertensive patient cohort were aged 60 years of age or older, with no symptoms or 
clinical signs of heart failure, normal LV EF with no significant valvular disease on screening 
echocardiography and no known cardiac or respiratory disease. Subjects were recruited 
prospectively from a large on-going hypertension database. 
 
 
Supplemental Table 1: Baseline Echocardiographic Characteristics of the HFpEF 
Cohort 
 
 
 HFpEF 
(n = 22) 
   
LV ejection fraction (%)  64.5 ± 7.9 
LV end-diastolic volume index (mL/m
2
)  36.4 (30.6 – 42.2) 
LA volume index (mL/m
2
)  28.0 ± 12.3 
LV mass index (g/m
2
)  109.0 ± 25.3 
E/A ratio  0.7 (0.6 – 1.1) 
E wave deceleration time, ms  185 ± 67 
e’ (mean of septal and lateral), cm/s  5.2 ± 1.5 
E/e’ ratio  11.1 ± 2.4 
   
 
Values are mean ± SD, percentages or median (quartiles 1 to 3).  LV = left ventricular; LA = 
left atrial; E = peak early diastolic mitral flow velocity; A = late diastolic mitral flow velocity; e’ 
= peak early diastolic mitral annular velocity. 
 
 
 
 
 
 
Supplemental Table 2:  Effect of Ivabradine versus Placebo on Resting Hemodynamic, 
Cardiac imaging and Exercise Parameters in the HFpEF Cohort 
 
 
Placebo 
(n = 22) 
Ivabradine 
(n = 22) 
   
Heart rate, beats/min (rest) 77 ± 13 57 ± 9 
Heart rate, beats/min (exercise) 129 ± 20 107 ± 18 
Systolic BP, mmHg 142 ± 25 149 ± 28 
Diastolic BP, mmHg  79 ± 12 76 ± 10 
LV end-diastolic volume index (mL/m
2
) 30.3 (26.7 – 40.0) 29.0 (25.8 – 40.0) 
LA volume index (mL/m
2
) 27.0 ± 10.7 31.3 ± 12.2 
LV mass index (g/m
2
) 109.0 ± 29.1 102.0 ± 22.5 
E/A ratio 0.60 (0.50 – 0.70) 0.65 (0.56 – 1.08) 
E wave deceleration time, ms 170 ± 44 177 ± 52 
VE/VCO2 36.1 ± 6.5 36.1 ± 6.1 
Anaerobic Threshold (mL/kg/min) 11.5 ± 2.9 10.4 ± 2.5 
RER 1.1 ± 0.1 1.1 ± 0.1 
OUES 1834 ± 563 1621 ± 347 
MRI LV ejection fraction (%) 74.1 ± 6.4 73.9 ± 7.2 
MRI LV end-diastolic volume index (mL/m
2
) 60.8 ± 11.7 64.8 ± 11.7 
MRI LV end-systolic volume index (mL/m
2
) 16.3 ± 6.7 17.5 ± 7.7 
MRI LV mass index (g/m
2
) 53.7 ± 12.3 52.1 ± 12.4 
MRS PCr/ATP ratio 1.69 ± 0.41 1.68 ± 0.39 
   
 
Values are mean ± SD, percentages or median (quartiles 1 to 3).  BP = blood pressure; LV = 
left ventricular; LA = left atrial; E = peak early diastolic mitral flow velocity; A = late diastolic 
mitral flow velocity; VE/VCO2 = minute ventilation-carbon dioxide production ratio; RER = 
respiratory exchange ratio; OUES = oxygen uptake efficiency slope; MRI = Magnetic 
Resonance Imaging;  
  
Supplemental Table 3: Effect of Ivabradine versus Placebo on Resting Hemodynamic, 
Cardiac Imaging and Exercise Parameters in the Asymptomatic Hypertensive Cohort 
 
 
Placebo 
(n = 22) 
Ivabradine 
(n = 22) 
   
Heart rate, beats/min (rest) 74 ± 14 61 ± 11 
Heart rate, beats/min (exercise) 145 ± 21 127 ± 23 
Systolic BP, mmHg 136 ± 19 144 ± 14 
Diastolic BP, mmHg  83 ± 13 75 ± 13 
LV end-diastolic volume index (mL/m
2
) 40.9 (28.4 – 55.0) 40.6 (34.7 – 58.0) 
LA volume index (mL/m
2
) 34.9 ± 14.1 40 ± 12.7 
LV mass index (g/m
2
) 85.7 ± 26.9 89.7 ± 24.1 
E/A ratio 0.84 ± 0.18 0.93 ± 0.19 
E wave deceleration time, ms 248 ± 56 269 ± 72 
VE/VCO2 27.4 ± 3.4 29.2 ± 3.5 
Anaerobic Threshold (mL/kg/min) 19.7 ± 5.9 19.4 ± 5.6 
RER 1.2 ± 0.1 1.2 ± 0 
OUES 1953 ± 511 1990 ± 447 
MRI LV ejection fraction (%) 65.0 ± 6.6 68.0 ± 7.4 
MRI LV end-diastolic volume index (mL/m
2
) 60.7 ± 20.1 61.6 ± 21.5 
MRI LV end-systolic volume index (mL/m
2
) 24.5 ± 8.3 22.8 ± 8.6 
MRI LV mass index (g/m
2
) 101.0 ± 21.2 107.0 ± 20.3 
MRS PCr/ATP ratio 1.81 ± 0.84 1.49 ± 0.69 
   
Values are mean ± SD, percentages or median (quartiles 1 to 3).  BP = blood pressure; LV = 
left ventricular; LA = left atrial; E = peak early diastolic mitral flow velocity; A = late diastolic 
mitral flow velocity; VE/VCO2, minute ventilation-carbon dioxide production ratio; RER = 
respiratory exchange ratio; OUES = oxygen uptake efficiency slope; MRI = Magnetic 
Resonance Imaging;  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1: Effect of Ivabradine on Selected Parameters of Exercise 
Performance in HFpEF and Asymptomatic Hypertensive Cohort 
 
 
 
 
 
 
 
The figures above depict the change in VO2 peak (mL/kg/min) from Placebo to 
Ivabradine in the HFpEF (left) and Hypertensive (right) cohorts (comparison is made 
between the VO2 peak values at the end of each intervention arm). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
The figures above show the effect of Placebo and Ivabradine on oxygen uptake 
efficiency slope (OUES) in the HFpEF (left) and Hypertensive (right) cohorts. 
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